A Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04148313|
Recruitment Status : Recruiting
First Posted : November 1, 2019
Last Update Posted : March 9, 2020
|Condition or disease||Intervention/treatment|
|Multiple Sclerosis MS||Other: No Intervention|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis|
|Actual Study Start Date :||March 2, 2020|
|Estimated Primary Completion Date :||March 2023|
|Estimated Study Completion Date :||July 2023|
Patients with diagnosis of Multiple Sclerosis.
Other: No Intervention
There is no intervention for this study.
- Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing [ Time Frame: One year ]Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized among specific disease types.
- Validation of Sequencing Methods [ Time Frame: One year ]To validate the methods used to sequence samples
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04148313
|Contact: Sabine Hazan, MDemail@example.com|
|Contact: Jordan Daniels, MSfirstname.lastname@example.org|
|Principal Investigator:||Sabine Hazan, MD||ProgenaBiome|